Facebook Linkedin Mail Twitter Youtube
  • Home
  • Research
  • Blog
  • TRIPS Flexibilities Database
  • Other Resources
    • Covid-19
    • Tools
      • Introduction
      • Model Government Use Licences
      • Model Uses of Paragraph 7 or “LDC Waiver”
      • Special Compulsory Licences for Export of Medicines
      • Options for Regional Economic Communities
      • Voluntary Licences
    • Useful Links
  • About
Search
Menu

Explore the website

Technical Briefing Papers

Deep dives into and analysis of issues that impact access to medicines.

Our Work on Covid-19

Our views on what governments and the international community can do to fight this pandemic and prepare for the next one.

Our Blog

Timely and topical analysis on the day-to-day issues in intellectual property and health.

The TRIPS Flexibilities Database

Instances when authorities have invoked, planned to/were asked to invoke a flexibility contained in the TRIPS Agreement for public health reasons.

Tools for Access to Medicines

Tools to help governments and others looking to increase access to medicines by using flexibilities in intellectual property law.

Meet the Team

Learn about Medicines Law & Policy's team of legal and policy experts.

Medicines Law & PolicyResearch and resources on intellectual property and health
Twitter
Linkedin
Facebook
Medicines Law & Policy
Research and resources
on intellectual property and health.
Contact Us
Subscribe

Subscribe to our newsletter and never miss a post!

* indicates required

Medicines Law & Policy will use the information you provide to keep you up-to-date when we post new research and insight. You can change your mind about receiving our newsletter any time by clicking the unsubscribe link in the footer of any email you receive from us. We will treat your information with respect. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

Menu

Explore the website

Technical Briefing Papers

Deep dives into and analysis of issues that impact access to medicines.

Our Work on Covid-19

Our views on what governments and the international community can do to fight this pandemic and prepare for the next one.

Our Blog

Timely and topical analysis on the day-to-day issues in intellectual property and health.

The TRIPS Flexibilities Database

Instances when authorities have invoked, planned to/were asked to invoke a flexibility contained in the TRIPS Agreement for public health reasons.

Tools for Access to Medicines

Tools to help governments and others looking to increase access to medicines by using flexibilities in intellectual property law.

Meet the Team

Learn about Medicines Law & Policy's team of legal and policy experts.

  • Home
  • Research
  • Blog
  • TRIPS Flexibilities Database
  • Other Resources
    • Covid-19
    • Tools
      • Introduction
      • Model Government Use Licences
      • Model Uses of Paragraph 7 or “LDC Waiver”
      • Special Compulsory Licences for Export of Medicines
      • Options for Regional Economic Communities
      • Voluntary Licences
    • Useful Links
  • About

Tag: Delinkage

How not to solve a crisis: The European Commission’s Plan for...

Ellen 't Hoen - March 3, 2023

Time for new pharmaceutical-innovation models

Ellen 't Hoen - February 11, 2020

Strong call for transparency on medicine prices, cost of R&D at...

Ellen 't Hoen - April 19, 2019

Wrapping Up 2017 – some noteworthy medicines law and policy events.

Ellen 't Hoen - December 31, 2017

UN High-Level Panel on Access to Medicines calls for stronger public...

Ellen 't Hoen - September 15, 2016

Recent Posts

  • The European Commission’s proposal on a new EU-wide compulsory licensing regime
  • The European Commission’s compulsory licensing proposals are sensible but do not go far enough
  • Thanks to the European Commission, Biogen can extend Tecfidera monopoly for at least two more years.
  • Submission to the US International Trade Commission

Posts by Subject

Access to Medicines Access to Vaccines ARIPO C-TAP Cancer CDCA competition law Compulsory licensing compulsory licensing for export covid-19 Covid-19 Pool Covid-19 vaccine cystic fibrosis Data exclusivity Delinkage DNDi essential medicines list European Commission European Union evergreening Fair Pricing Gilead Hepatitis C IFPMA INB LDCs market exclusivity Medicines Patent Pool Medicines Pricing Netherlands orkambi Orphan Drugs pandemic treaty Patents R&D remdesivir Sofosbuvir The Netherlands transparency TRIPS flexibilities TRIPS Flexibilities Database TRIPS Waiver vaccines WHO WTO

Medicines Law & Policy

Facebook
Linkedin
Twitter

Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.

  • Home
  • Research
  • Blog
  • TRIPS Flexibilities Database
  • Tools
  • Covid-19
  • Useful Links
  • About
  • TRIPS Flexibilities Database
  • Other resources

Never miss a post! Sign up for ML&P's mailing list by entering your information below. The list will only be used to inform you of new content (messages are sent approximately once a month).

* indicates required






Medicines Law & Policy will use the information you provide to keep you up-to-date when we post new research and insight. You can change your mind about receiving our newsletter any time by clicking the unsubscribe link in the footer of any email you receive from us. We will treat your information with respect. By clicking below, you agree that we may process your information in accordance with these terms. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

 
 

This work is licensed under Creative Commons. You are free to share, with attribution and without changes, for non-commercial purposes.